Preparation method of tofacitinib impurity

Tofatinib impurities were prepared through multiple-step reactions of compound I and compound II under specific conditions, and the problem of lack of this impurity synthesis method in the prior art was solved. Standard samples were provided for tofatinib research. It also demonstrates an efficient and environmentally friendly preparation process.

CN118894853AInactive Publication Date: 2024-11-05TLC NANJING PHARMA RANDD CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410928404.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-11
Publication Date
2024-11-05
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The lack of synthesis methods for tofatinib impurities in the prior art makes it difficult to conduct comprehensive research on its clinical, pharmacological, pharmacokinetic and toxicological analysis.

Method used

Tofatinib impurities were prepared by performing a series of reactions under the action of different solvents and catalysts, including nucleophilic substitution, hydrolysis, debenzyl removal, amidation and cyanation reactions.

Benefits of technology

It realizes the efficient preparation of tofatinib impurities and provides standard samples for clinical and pharmacological research, with reasonable process, simple operation and good environmental protection effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118894853A_ABST
    Figure CN118894853A_ABST
Patent Text Reader

Abstract

The invention discloses a tofacitinib impurity preparation method, which comprises: (1) using a compound I and a compound II as raw materials, and carrying out a nucleophilic substitution reaction to obtain an intermediate product III; (2) carrying out hydrolysis reaction on the intermediate product III under an acidic condition to generate an intermediate product IV; (3) removing benzyl from the intermediate product IV to obtain an intermediate product V; (4) carrying out amidation reaction on the intermediate product V and chloroacetyl chloride to obtain an intermediate product VI; and (5) carrying out cyanation reaction on the intermediate product VI and tetrabutylammonium cyanide to obtain a final product VII. The method has the advantages of reasonable process design, simple operation method, easily available raw materials, high purity, controllable reaction process and good environmental protection effect; the prepared tofacitinib impurity provides a test sample for the research of tofacitinib, and has important research value in the clinical pharmacokinetic research.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a method for preparing a compound, and in particular to a method for preparing tofacitinib impurities. Background Art

[0002] Tofacitinib is a drug developed by Pfizer Pharmaceuticals in the United States to treat rheumatoid arthritis. It is used for adult patients with moderate to severe active rheumatoid arthritis (RA) who have an inadequate response or intolerance to methotrexate. It can effectively inhibit the activity of JAK1 and JAK3 and block the signal transduction of multiple inflammatory cytokines. Existing studies have shown that tofacitinib has a good therapeutic effect on a variety of inflammatory-related diseases such as rheumatoid arthritis, ulcerative colitis, and psoriasis.

[0003] With the progress of the times and the improvement of science and technology, people have a better understanding of the importance of scientific evaluation of drug quality, safety and efficacy before the drug is put on the market. Among them, the control of impurities contained in the drug is closely related to the quality of the drug. Impurities are often related to drug safety, and in a few cases, they are also related to efficacy. Therefore, controlling the level of impurities is increasingly valued by medical workers in the process of drug development and research.

[0004] This impurity is generated during the synthesis and storage of tofacitinib, and there is no public synthesis method for this impurity. In order to conduct a comprehensive analysis and study of the clinical, pharmacological, pharmacokinetics, and toxicology of tofacitinib, it is necessary to design and develop a preparation method for tofacitinib impurities based on existing technologies, so as to provide a reference substance for the comprehensive analysis of the clinical, pharmacological, pharmacological, and toxicological aspects of tofacitinib. Summary of the invention

[0005] Purpose of the invention: The present invention aims to provide a method for preparing tofacitinib impurities.

[0006] Technical solution: The method for preparing tofacitinib impurities of the present invention comprises the following steps:

[0007] (1) Compound I and Compound II are used as raw materials, a solvent is added, a base is added, and a nucleophilic substitution reaction is carried out to obtain an intermediate product III. The synthetic route is as follows:

[0008]

[0009] (2) Take the intermediate product III prepared in step (1), add a solvent, add an acid, and perform a hydrolysis reaction to generate an intermediate product IV. The synthetic route is as follows:

[0010]

[0011] (3) The intermediate product IV obtained in step (2) is dissolved in a solvent, a catalyst is added, and then ammonium formate is added to remove the benzyl group to obtain the intermediate product V. The synthetic route is as follows:

[0012]

[0013] (4) The intermediate product V obtained in step (3) is dissolved in tetrahydrofuran, chloroacetyl chloride is added, and then a base is added to carry out an amidation reaction to obtain the intermediate product VI. The synthetic route is as follows:

[0014]

[0015] (5) The intermediate product VI obtained in step (4) is dissolved in a solvent, and tetrabutylamine cyanide is added to carry out a cyanation reaction to obtain the final product VII. The synthesis route is as follows:

[0016]

[0017] Preferably, in step (1), the reaction temperature is 20-30°C.

[0018] Preferably, in step (1), the molar ratio of compound I to base is (1:1) to (1:5). The base is sodium hydride, lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate or triethylamine; the reaction time is 6 to 24 hours. Further preferably, the base is sodium carbonate, and the reaction time is 12 to 18 hours.

[0019] Preferably, in step (1), the reaction solvent is methanol.

[0020] Preferably, in step (2), the reaction temperature is 40 to 60° C., and the reaction time is 1 to 16 hours.

[0021] Preferably, in step (2), the acid is hydrochloric acid, sulfuric acid, formic acid, trifluoroacetic acid or acetic acid. Further preferably, the acid is acetic acid; and the reaction time is 5 to 10 hours.

[0022] Preferably, in step (2), the reaction solvent is ethanol.

[0023] Preferably, in step (3), the reaction temperature is 10 to 30° C. for 2 to 24 hours, and the reaction catalyst is palladium carbon.

[0024] Preferably, in step (3), the molar ratio of the intermediate product IV to ammonium formate is (1:1) to (1:8). Further preferably, the reaction time is 8 to 16 hours.

[0025] Preferably, in step (3), the reaction solvent is methanol.

[0026] Preferably, in step (4), the reaction temperature is 60 to 80° C., and the reaction time is 2 to 20 hours.

[0027] Preferably, in step (4), the molar ratio of the intermediate product V to the base is (1:1) to (1:4); further preferably, the reaction time is 8 to 16 hours.

[0028] Preferably, in step (4), the base is triethylamine, sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide or sodium hydride.

[0029] Preferably, in step (4), the reaction solvent is tetrahydrofuran.

[0030] Preferably, in step (5), the reaction temperature is 50 to 70° C. and the reaction time is 1 to 10 hours.

[0031] Preferably, in step (5), the molar ratio of the intermediate product V to tetrabutylammonium cyanide is (1:1) to (1:5). Further preferably, the reaction time is 2 to 6 hours.

[0032] Preferably, in step (5), the reaction solvent is methanol.

[0033] Beneficial effects: Compared with the prior art, the present invention has the following significant advantages: (1) The method and process design are reasonable, the operation method is simple, the raw materials are easily available, the purity is high, the reaction process is controllable, and the environmental protection effect is good; (2) The prepared tofacitinib impurities provide test samples for the research of tofacitinib, which has important research value in clinical pharmacokinetic research. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 A synthetic route for the preparation of the tofacitinib impurities provided by the present invention;

[0035] Figure 2 The final product NMR of the tofacitinib impurities provided by the present invention;

[0036] Figure 3 The final product liquid phase of the tofacitinib impurities provided by the present invention. DETAILED DESCRIPTION

[0037] The technical solution of the present invention is further described below in conjunction with embodiments.

[0038] Example 1

[0039] The method for preparing tofacitinib impurities of the present invention comprises the following steps:

[0040] (1) Preparation of intermediate product III: 10 g of compound I was dissolved in 200 mL of methanol, 22.6 g of sodium carbonate and 11.6 g of compound II were added, and the mixture was reacted at 25° C. for 16 hours. After the reaction was completed, the mixture was filtered and the reaction solution was spin-dried. The crude product was purified by column chromatography using dichloromethane and methanol in a volume ratio of 30:1 to obtain 17 g of brown solid III with a yield of 86%.

[0041]

[0042] (2) Preparation of intermediate product IV: 17 g of intermediate product III was dissolved in 170 mL of ethanol, 17 mL of acetic acid was added at 25° C., and the mixture was reacted at 50° C. for 8 hours. The reaction was completed by monitoring by TLC. The reaction solution was spin-dried, 200 mL of water was added, and saturated aqueous sodium bicarbonate solution was added under ice bath to adjust the pH to 8. The mixture was extracted with dichloromethane three times, 50 mL each time. The organic layers were combined and dried over anhydrous sodium sulfate, filtered, and the filtrate was spin-dried to obtain a crude product. The crude product was purified by column chromatography using dichloromethane and methanol in a volume ratio of 25:1 to obtain 15 g of yellow solid IV. The yield was 92%.

[0043]

[0044] (3) Preparation of intermediate product V: 10 g of intermediate product IV was dissolved in 100 mL of methanol solvent, 0.5 g of palladium carbon was added, and then 7.2 g of ammonium formate was added. The reaction solution was reacted at 25° C. for 12 hours. The reaction was monitored by TLC (developing solvent: dichloromethane: methanol volume ratio = 15:1). The reaction solution was spin-dried, 100 mL of water was added, and extracted with dichloromethane three times, 50 mL each time. The organic layers were combined and dried over anhydrous sodium sulfate, filtered, and the filtrate was spin-dried to obtain 7 g of yellow solid V. The yield was 94%.

[0045]

[0046] (4) Preparation of intermediate product VI: 5 g of intermediate product V was dissolved in 50 mL of tetrahydrofuran, 2.2 g of chloroacetyl chloride and 7.7 g of triethylamine were added, and the mixture was reacted at 70° C. for 12 hours. After the reaction of the raw materials was completed, the reaction solution was dried by rotary evaporation, and the crude product was purified by column chromatography using dichloromethane and methanol in a volume ratio of 30:1 to obtain 4.3 g of white solid VI, with a yield of 82%.

[0047]

[0048] (5) Preparation of intermediate product VII: 2 g of intermediate product VI was dissolved in 20 mL of methanol, and 4.8 g of tetrabutylammonium cyanide was added to react at 65°C for 4 hours. After the reaction of the raw materials was completed, the reaction solution was spin-dried and the crude product was purified by column chromatography using dichloromethane and methanol in a volume ratio of 30:1 and then recrystallized from acetonitrile to obtain 1.7 g of light yellow solid VII with a yield of 87.4%.

[0049]

[0050] The NMR spectrum of the product compound VII is shown in Figure 2 , from the figure, we can get 1 H NMR(400MHz, CDCl3)δ8.95(d,1H),8.26(d,1H),4.88(m,1H),4.01-3.72(m,4H) ,3.59-3.47(m,4H),3.18(d,3H),2.39(m,1H),1.92-1.70(m,2H),1.10(m,3H).

[0051] Liquid Phase Figure 3 ,HPLC:99.26%.

[0052] Example 2

[0053] The method for preparing tofacitinib impurities of the present invention comprises the following steps:

[0054] (1) Preparation of intermediate product III: 10 g of compound I was dissolved in 200 mL of methanol, 5.6 g of sodium carbonate and 11.6 g of compound II were added, and the mixture was reacted at 25° C. for 6 hours. After the reaction was completed, the mixture was filtered and the reaction solution was spin-dried. The crude product was purified by column chromatography using dichloromethane and methanol in a volume ratio of 30:1 to obtain 15 g of brown solid III with a yield of 76%.

[0055]

[0056] (2) Preparation of intermediate product IV: 15 g of intermediate product III was dissolved in 150 mL of ethanol, 10 mL of 6 M HCl was added at 25° C., and the mixture was reacted at 50° C. for 16 hours. The reaction was monitored by TLC (developing solvent: dichloromethane: methanol, volume ratio = 25:1). The reaction solution was spin-dried, 200 mL of water was added, and the mixture was extracted three times with 50 mL of dichloromethane each time. The organic layers were combined and dried over anhydrous sodium sulfate, filtered, and the filtrate was spin-dried to obtain a crude product. The crude product was purified by column chromatography using dichloromethane: methanol, volume ratio = 25:1 to obtain 11 g of yellow solid IV, with a yield of 77%.

[0057]

[0058] (3) Preparation of intermediate product V: 10 g of intermediate product IV was dissolved in 100 mL of methanol solvent, 0.5 g of palladium carbon was added, and then 1.8 g of ammonium formate was added. The reaction solution was reacted at 25° C. for 24 hours. The reaction was monitored by TLC (developing solvent: dichloromethane: methanol volume ratio = 15:1). The reaction solution was spin-dried, 100 mL of water was added, and extracted with dichloromethane three times, 50 mL each time. The organic layers were combined and dried over anhydrous sodium sulfate, filtered, and the filtrate was spin-dried to obtain 6.3 g of yellow solid V, with a yield of 84%.

[0059]

[0060] (4) Preparation of intermediate product VI: 5 g of intermediate product V was dissolved in 50 mL of tetrahydrofuran, 2.2 g of chloroacetyl chloride and 1.9 g of triethylamine were added, and the mixture was reacted at 70° C. for 20 hours. After the reaction of the raw materials was completed, the reaction solution was spin-dried and the crude product was purified by column chromatography using dichloromethane and methanol in a volume ratio of 30:1 to obtain 4.5 g of white solid VI with a yield of 69%.

[0061]

[0062] (5) Preparation of intermediate product VII: 2 g of intermediate product VI was dissolved in 20 mL of methanol, and 1.6 g of tetrabutylammonium cyanide was added to react at 65° C. for 10 hours. After the reaction of the raw materials was completed, the reaction solution was spin-dried and the crude product was purified by column chromatography using dichloromethane and methanol in a volume ratio of 30:1 to obtain 1.5 g of light yellow solid VII with a yield of 77%.

[0063]

[0064] Example 3

[0065] The method for preparing tofacitinib impurities of the present invention comprises the following steps:

[0066] (1) Preparation of intermediate product III: 10 g of compound I was dissolved in 200 mL of methanol, 8.5 g of sodium hydroxide and 11.6 g of compound II were added, and the mixture was reacted at 25° C. for 16 hours. After the reaction was completed, the mixture was filtered and the reaction solution was spin-dried. The crude product was purified by column chromatography using dichloromethane and methanol in a volume ratio of 30:1 to obtain 14 g of brown solid III with a yield of 71%.

[0067]

[0068] (2) Preparation of intermediate product IV: 14 g of intermediate product III was dissolved in 140 mL of ethanol, 14 mL of trifluoroacetic acid was added at 25° C., and the mixture was reacted at 50° C. for 8 hours. The reaction was monitored by TLC (developing solvent: dichloromethane: methanol in a volume ratio of 15:1). The reaction solution was spin-dried, 200 mL of water was added, and saturated aqueous sodium bicarbonate solution was added under ice bath to adjust the pH to 8. The mixture was extracted with dichloromethane three times, 50 mL each time. The organic layers were combined and dried over anhydrous sodium sulfate, filtered, and the filtrate was spin-dried to obtain a crude product. The crude product was purified by column chromatography using dichloromethane: methanol in a volume ratio of 25:1 to obtain 10.6 g of yellow solid IV, with a yield of 79%.

[0069]

[0070] (3) Preparation of intermediate product V: 10 g of intermediate product IV was dissolved in 100 mL of methanol solvent, 0.5 g of palladium carbon was added, and then 14.3 g of ammonium formate was added. The reaction solution was reacted at 25° C. for 12 hours. The reaction was monitored by TLC (developing solvent: dichloromethane: methanol volume ratio = 15:1). The reaction solution was spin-dried, 100 mL of water was added, and extracted with dichloromethane three times, 50 mL each time. The organic layers were combined and dried over anhydrous sodium sulfate, filtered, and the filtrate was spin-dried to obtain 6.7 g of yellow solid V, with a yield of 90%.

[0071]

[0072] (4) Preparation of intermediate product VI: 4 g of intermediate product V was dissolved in 40 mL of tetrahydrofuran, 1.7 g of chloroacetyl chloride and 4.8 g of sodium carbonate were added, and the mixture was reacted at 70° C. for 12 hours. After the reaction of the raw materials was completed, the reaction solution was spin-dried and the crude product was purified by column chromatography using dichloromethane and methanol in a volume ratio of 30:1 to obtain 3.7 g of white solid VI with a yield of 71%.

[0073]

[0074] (5) Preparation of intermediate product VII: 2 g of intermediate product VI was dissolved in 20 mL of methanol, and 8.0 g of tetrabutylammonium cyanide was added to react at 65° C. for 4 hours. After the reaction of the raw materials was completed, the reaction solution was spin-dried and the crude product was purified by column chromatography using dichloromethane and methanol in a volume ratio of 30:1 to obtain 1.3 g of light yellow solid VII with a yield of 66.9%.

[0075]

Claims

1. A method for preparing tofacitinib impurities, characterized in that: The following steps are involved: (1) Compound I and Compound II are used as raw materials, a solvent is added, a base is added, and a nucleophilic substitution reaction is carried out to obtain an intermediate product III. The synthetic route is as follows: (2) Take the intermediate product III prepared in step (1), add a solvent, add an acid, and perform a hydrolysis reaction to generate an intermediate product IV. The synthetic route is as follows: (3) The intermediate product IV obtained in step (2) is dissolved in a solvent, a catalyst is added, and then ammonium formate is added to remove the benzyl group to obtain the intermediate product V. The synthetic route is as follows: (4) The intermediate product V obtained in step (3) is dissolved in tetrahydrofuran, chloroacetyl chloride is added, and then a base is added to carry out an amidation reaction to obtain the intermediate product VI. The synthetic route is as follows: (5) The intermediate product VI obtained in step (4) is dissolved in a solvent, and tetrabutylamine cyanide is added to carry out a cyanation reaction to obtain the final product VII. The synthesis route is as follows:

2. The method for preparing tofacitinib impurities according to claim 1, characterized in that: In step (1), the reaction temperature is 20-30°C.

3. The method for preparing tofacitinib impurities according to claim 1, characterized in that: In step (1), the molar ratio of compound I to base is (1:1) to (1:5).

4. The method for preparing tofacitinib impurities according to claim 1, characterized in that: In step (2), the reaction temperature is 40-60°C.

5. The method for preparing tofacitinib impurities according to claim 1, characterized in that: In step (3), the molar ratio of the intermediate product IV to ammonium formate is (1:1) to (1:8).

6. The method for preparing tofacitinib impurities according to claim 1, characterized in that: In step (4), the reaction temperature is 60-80°C.

7. The method for preparing tofacitinib impurities according to claim 1, characterized in that: In step (4), the molar ratio of the intermediate product V to the base is (1:1) to (1:4).

8. The method for preparing tofacitinib impurities according to claim 1, characterized in that: In step (5), the reaction temperature is 50-70°C.

9. The method for preparing tofacitinib impurities according to claim 1, characterized in that: In step (5), the molar ratio of the intermediate product V to tetrabutylammonium cyanide is (1:1) to (1:5).

10. The method for preparing tofacitinib impurities according to claim 1, characterized in that: In step (1) or (4), the base is sodium hydride, lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate or triethylamine.